Belzutifan is a CYP2C19 substrate. Coadministration with CYP2C19 inhibitors might maximize incidence or severity of adverse effects. Monitor for anemia and hypoxia and lower belzutifan dose as recommended.Drug Interactions Whilst specified medicines should not be applied with each other whatsoever, in other cases two diverse medicines could possibl